Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.

[1]  Maarten de Rooij,et al.  Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. , 2014, European urology.

[2]  A. Villers.  Words of wisdom. Re: Improving detection of clinically significant prostate cancer: MRI/TRUS fusion-guided prostate biopsy. , 2014, European urology.

[3]  Baris Turkbey,et al.  Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. , 2014, The Journal of urology.

[4]  Ruth Etzioni,et al.  Overdiagnosis and overtreatment of prostate cancer. , 2014, European urology.

[5]  U. Patel.  Histology core‐specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate , 2013, BJU international.

[6]  Baris Turkbey,et al.  Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. , 2013, European urology.

[7]  J. Fütterer,et al.  Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. , 2013, European urology.

[8]  B. G. Blijenberg,et al.  Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. , 2013, European urology.

[9]  Walter Artibani,et al.  Early detection of prostate cancer: European Association of Urology recommendation. , 2013, European urology.

[10]  J. Barentsz,et al.  Prostate cancer: MRI/US-guided biopsy—a viable alternative to TRUS-guidance , 2013, Nature Reviews Urology.

[11]  L. Klotz,et al.  Prostate cancer overdiagnosis and overtreatment , 2013, Current opinion in endocrinology, diabetes, and obesity.

[12]  P. P. Iu,et al.  ESUR prostate MR guidelines. , 2013, European radiology.

[13]  W. Butler,et al.  Transperineal Template-guided Mapping Biopsy as a Staging Procedure to Select Patients Best Suited for Active Surveillance , 2013, American journal of clinical oncology.

[14]  H. Ahmed,et al.  Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. , 2013, The Journal of urology.

[15]  G. Andriole.  Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer , 2013 .

[16]  P. Dahm,et al.  Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.

[17]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[18]  Thomas Hambrock,et al.  Simulated required accuracy of image registration tools for targeting high-grade cancer components with prostate biopsies , 2013, European Radiology.

[19]  P. Mozer,et al.  Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. , 2012, European urology.

[20]  R. V. D. van den Bergh,et al.  Outcomes of initially expectantly managed patients with low or intermediate risk screen‐detected localized prostate cancer , 2012, BJU international.

[21]  L. R. Jensen,et al.  Peripheral Zone Prostate Cancer Localization by Multiparametric Magnetic Resonance at 3 T: Unbiased Cancer Identification by Matching to Histopathology , 2012, Investigative radiology.

[22]  Anssi Auvinen,et al.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.

[23]  T. Scheenen,et al.  Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. , 2012, Radiology.

[24]  D. Hawkes,et al.  The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. , 2012, The Journal of urology.

[25]  H. D. de Koning,et al.  Quality-of-life effects of prostate-specific antigen screening. , 2012, The New England journal of medicine.

[26]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[27]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[28]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[29]  J. Lau,et al.  Active surveillance in men with localized prostate cancer: a systematic review. , 2012, Annals of internal medicine.

[30]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[31]  G. Haber,et al.  Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging‐targeted and systematic biopsy for significant prostate cancer detection , 2011, BJU international.

[32]  Kirsten L. Greene,et al.  Outcomes of active surveillance for men with intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Theodorus H van der Kwast,et al.  A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. , 2011, The Journal of urology.

[34]  P. Choyke,et al.  Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. , 2010, Radiology.

[35]  Thomas Hambrock,et al.  Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. , 2010, The Journal of urology.

[36]  James D. Stamey,et al.  Bayesian Interval Estimation for Predictive Values from Case-Control Studies , 2009, Commun. Stat. Simul. Comput..

[37]  Pär Stattin,et al.  Prostate specific antigen for early detection of prostate cancer: longitudinal study , 2009, BMJ : British Medical Journal.

[38]  Clare Allen,et al.  Is it time to consider a role for MRI before prostate biopsy? , 2009, Nature Reviews Clinical Oncology.

[39]  Xiao-Hua Zhou,et al.  Confidence intervals for predictive values with an emphasis to case–control studies , 2007, Statistics in medicine.

[40]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[41]  W O Johnson,et al.  Estimation of sensitivity and specificity of diagnostic tests and disease prevalence when the true disease state is unknown. , 2000, Preventive veterinary medicine.

[42]  S. Walter,et al.  Estimating the error rates of diagnostic tests. , 1980, Biometrics.